KRYS News and Press, Krystal Biotech Inc. From 08/21/23

PITTSBURGH, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced t...

2023-08-07 07:18:11 ET Krystal Biotech press release ( NASDAQ: KRYS ): Q2 GAAP EPS of -$1.25 misses by $0.51 . Cash, cash equivalents, and investments totaled $505.9 million on June 30, 2023. For further details see: Krystal Biotech GAAP EPS of -$1.25 mi...

• VYJUVEK™ approved in the U.S. as the first and only topical redosable gene therapy for the treatment of dystrophic epidermolysis bullosa • 121 Patient Start Forms in the first six weeks of launch • First cystic fibrosis patient dosed in Phase 1...

2023-07-31 22:26:21 ET Summary Krystal Biotech's FDA-approved gene therapy for DEB sets a medical milestone, opening new revenue streams. With a robust financial health, Krystal prepares to launch a diverse pipeline of innovative gene therapies. Despite potential rewards, risi...

PITTSBURGH, July 26, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, anno...

2023-07-21 08:15:00 ET Investors looking for stocks with explosive growth potential would do well to take a gander at the biotech industry. Clinical and regulatory wins can fuel excellent stock market performances for companies in the sector in a relatively short period, say a year. But sho...

PITTSBURGH, July 03, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with debilitating diseases, announced today that the first patient has been do...

Krystal Biotech, Inc. (NASDAQ: KRYS) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.59% on the day to $128.12. Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the Un...

PITTSBURGH, June 05, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the fo...

2023-06-03 08:30:00 ET This year has been a good one for equity markets so far, but even by that standard, some stocks are doing incredibly well. That's the case with Krystal Biotech (NASDAQ: KRYS) , a mid-cap company that is already up 48% in 2023. As is often the case in this ...